Table 2.
Demographics, viral loads, cART regimens and DRM’s of 11 individuals with multi-class drug resistance in Botswana.
| Patient # | ART Initiation Date | Date Sample Collected | Age at Sample Collection | Gender | VL of Sample Collected for GRT (cps/mL) | ART Regimen at Time of Sampling of GRT | Prior Exposure to RAL (Yes/No) | Major DRM’s Β | Current ART Regimen | Current VL (cps/mL) | Date of Current VL | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RT(NRTI; NNRTI) | PI | INSTI | |||||||||||
| 1 (139-0007-8) |
27-Apri-06 | 31-May-17 | 40 | M | 69,510 | TDF/FTC/DRV\r/DTG | NO | D67N, K70R, M184V, T215I, K219E; A98G, V106I, Y188L |
NONE | E138K, G140A, Q148K, (A128T) | TDF/FTC/DRV\r/DTG 200/300 mg od/600\100 mg bd/50 mg bd |
<400 | 10-Sep-20 |
| 2 (139-0006-2) |
25-Nov-03 | 21-Jun-17 | 38 | F | 826 | TDF/FTC/DTG | YES | M184V; K101E, G190S |
NONE | Q148R | TDF/FTC/DTG 200/300 mg OD/50 mg BD |
<50 | 22-Jul-20 |
| 3 (139-0008-6) |
21-Sept-11 | ± 10-Jan-18 | 43 | M | * <400 | AZT/3TC/DTG | NO | A62V, K65R, M184V; K103N, V106M |
NONE | G118R, E138K | 3TC/DRV\r/DTG (150 BD/600\100 BD/50 OD) |
<25 | 02-Sep-20 |
|
∞ 4a (139-0009-5a) |
14-May-07 | 19-Apr-17 | 41 | F | 119,563 | ABC/3TC/DTG | YES | M184V, T215Y; K103S, G190A |
NONE | S147G, N155H, D232N | TDF/FTC/DRV\r/DTG (300/200 mg od/600\100 mg bd/50 mg bd) |
<25 | 11-Jun-20 |
|
∞ 4b (139-0009-5b) |
± 18-May-18 | 42 | F | 79,028 | ABC/3TC/DTG | YES | M184V, T215Y; K103S, G190A |
NONE | S147G, N155H, D232N | TDF/FTC/DRV\r/DTG (300/200 mg od/600\100 mg bd/50 mg bd) |
<25 | 11-Jun-20 | |
| 5 (139-0147-0) |
27-Nov-06 | 28-Jun-17 | 21 | M | 815 | TDF/FTC/DTG | NO | ND | ND | N155ND | TDF/FTC/DTG 300/200/mg OD/50 mg BD |
12,304 | 24-Jul-19 |
| 6 (139-0002-8) |
22-Sept-03 | 01-Nov-17 | 51 | M | 515 | TDF/FTC/DRV\r/DTG | YES | *+ K70R, M184V; K219N/Y181C 20APRIL2009) * ¥ D67N, K70R, M184V/ NONE (18AUG2016) |
*+ V32I, I47V, I54L, I84V (20 APRIL2009) * ¥ V32I, I47V, I54L, I84V (18AUG2016) |
E138K, G140A, S147G, Q148R, (T97A) | TDF/3TC/DRV\r/DTG (300/300 mg OD/600\100 BD/50 mg BD) |
22,690 | 31-Aug-20 |
| 7 (139-0004-6) |
19-May-04 | 06-Apr-18 | 45 | M | * 55,342 | AZT/3TC/DTG | NO | M41L, T69G, K70R, M184V, T215C, K219E; A98G, K101E |
M46I, I54V, L76V, V82A | T66A, G118R, E138EAKT | TDF/FTC/DRV\r/DTG 300/200 mg OD/600\100 mg BD/50 mg OD |
992 | 13-Oct-20 |
| 8 (139-0003-4) |
25-June-04 | 11-Apr-18 | 41 | F | 50,699 | TDF/FTC/RAL | YES | M184V, T215Y; NONE |
NONE | E138K, G140A, Q148R | TDF/3TC/DRV\r/DTG 300/300 mg OD/600\100 mg BD/50 mg BD |
<25 | 22-Jul-20 |
| 9 (139-0001-8) |
7-May-01 | 06-Dec-18 | 55 | M | 9775 | TDF/3TC/DTG | YES | M41L, D67N, K70KR, V75M, M184V, L210W, T215Y, K219E; A98G, Y181C, G190A |
M46I, I47V, I54L, L76V, I84V, Q58E, N83D | E138K, S147G, Q148R, N155H, (E157Q) | TDF/3TC/DTG | 177,268 | 13-Feb-20 |
| 10 (139-0011-3) |
6-Feb-04 | 13-May-15 | 50 | F | 1300 | TDF/FTC/DRV\r/RAL | YES | **+ D67N, K70R, K219E/K101Q, K103N (7DEC2009) ** ¥ NONE/P225H (10FEB2012) |
**+ NONE(7DEC2009) ** ¥ NONE (10FEB2012) |
N155H | TDF/FTC/DRV\r/DTG 300/200 mg OD/600\100 mg BD/50 mg BD |
<400 | 10 Jan 2020 |
| 11 (139-0012-9) |
3-Oct-02 | 18-May-15 | 44 | M | * 2300 | TDF/FTC/DRV\r/RAL | YES | Major; M184V, M41L, T215Y: NONE |
Major; M46I, V82A Accessory; L24I |
N155NH (D232DN) | AZT/3TC/DRV\r/DTG 450 mg BD/600\100 mg BD/50 mg BD |
<50 | 26-Aug-20 |
Β Major DRMs as determined by the Stanford HIV drug resistance database. ± Date sample collected not written on requisition forms, used date sample received in a testing laboratory and/or date samples testing started and/or results issued. * No VL results available for the sample, used last recorded VL before sampling for GRT obtained from IPMS. Historical DRMs denoted with a ’*’. Historical DRMs refers to GRT performed on plasma samples from the same individuals but at a different time point (date in appendix table). *+ from sample GRT performed on 20 April 2009. * ¥ from sample GRT performed on 18 Aug 2016. **+ from sample GRT performed on 7 DEC 2009. ** ¥ from sample GRT performed on 10 FEB 2012. ∞ 4a and 4b are the same individual but their specimens were collected at different time points. Major INSTI DRMS column, DRMs listed within brackets “()” are accessory INSTI resistance mutations. VL, viral load; ART, antiretroviral therapy; GRT, genotypic resistance testing; cps/ml, copies/mL; RT, reverse transcriptase; NRTI, nucleoside/nucleotide reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; PR, protease; PI, protease inhibitor; INSTI, integrase strand transfer inhibitors; DRMs, drug resistance mutations; VL, viral load; GRT, genotypic resistance test; RAL, raltegravir; 3TC, Lamivudine; DRV\r, darunavir\ritonavir; DTG, dolutegravir; FTC, emtricitabine; TDF, tenofovir disoproxil fumarate; BD, twice a day dosing; OD, once a day dosing; mg, milligrams; ND, not done; IPMS, integrated patient management software (a laboratory information systems software). Green colour depicts virological suppression and red colour non virological suppression.